glp 1 agonist eli lilly Diabetes Patients Also Struggle to Access GLP-1 Agonists Lilly's Double-Beat Widens the GLP-1

While cardiovascular outcome data for retatrutide is still accumulating, the prudent approach for anyone with active cardiovascular disease is to remain on compounds with established cardiovascular safety profiles

Neeland IJ, Marso SP, Ayers CR, et al

Media coverage, online discussions, and high-profile public conversations around weight loss treatments have introduced GLP-1 therapy to a much wider audience than in the past

The primary outcome was MACE, a composite of myocardial infarction, stroke, and all-cause mortality

Methotrexate + Trimethoprim Severe bone marrow suppression 9

Abd El-Karim SS, Anwar MM, Syam YM, Nael MA, Ali HF, Motaleb MA